#asco24 search results

END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO…

Efficacy of first-line treatment options in advanced EGFR-mutated NSCLC From Stephanie P. L. Saw's presentation at #ASCO24 @OncoAlert

🟩🟦HAPPY BIRTHDAY🟦🟩 本日１２月１１日（水）は、 #加藤順大 コーチのお誕生日✨ お誕生日おめでとうございます🎊 #アトレチコ鈴鹿クラブ #ASCO24 #ASC

The study, previously presented at #ASCO24 and now published in @JCO_ASCO, based on the analysis of patients from the NCDB database, showed that omitting adjuvant endocrine therapy in ER-low tumors was associated with worse OS. In the discussion section of the article, the…

📢Treatment Algorithm for Essential Thrombocythemia (ET) 🔍Risk Assessment (IPSET): Age >60, prior thrombosis, CV risk, JAK2 💊Treatment: 🔹Very Low Risk: Observe 🔹Low: ASA 🔹Intermediate: ASA ± cytoreduction (if CV risk present 🔹 High Risk: ASA + cytoreduction (HU/INF) #ASCO24

Empowering change through #CancerAdvocacy & fundraising in Nigeria! In this conversation with @ecancer at #ASCO24, H.E Dr. Zainab Shinkafi Bagudu @DrZSB highlights the challenges & opportunities in improving cancer care and how collective efforts can drive lasting impact. Watch…

👌Excellent algorithm 🔍 First-line AML Treatment Simplified 📊 💡 Intensive vs Non-Intensive Chemotherapy 🔑 Highlights: ✅ FLT3 inhibitors, IDH inhibitors, CPX-351, HMA+Venetoclax 🩺 Tailored to patient fitness & ELN risk. 📚 #ASCO24 #Hematology #AML #Oncology

▶️Phase III TOPGEAR trial (LBA58 #ESMO24): Adding pre-op CRT to peri-op FLOT didn’t improve OS (46.4 vs 49.4) or PFS (31.4 vs 31.8 months) in resectable gastric/GE cancer. ESOPEC p3 trial (#ASCO24) confirms FLOT > CROSS for oesophageal/GEJ adenoca. 💡No role for pre-op CRT ⤵️

❗️ RTOG 0848 mOS 3.0 -> 3.9y with CRT 5-year OS 28.6% vs 48.1% CRT Stable tail effects > 5 years — more long term cured with CRT rather than chemo alone?! #asco24

The full text of the study by @Lucarecco et al., presented at #ASCO24, has now been published in @Annals_Oncology 💥In young BRCA carriers, luminal A-like disease has the worst DFS compared to other subtypes, and HR status is not a strong positive prognostic factor @OncoAlert…

1/3 🫁 IMpower-010 #ASCO24 🫁 🌟 DFS final analysis & second OS interim analysis 🌟 📌 PPT was prepared because it is a poster presentation and the display is small. 📌 First, a concrusion. @HwakeleeMD @ASCO abstract : #LBA8035

Still recovering from #ASCO24 but reflecting on how lucky we are to have a meeting that combines both amazing science & the best people! A bit bittersweet that this was my last year as @ASCOTECAG member & I’ll miss this amazing group so much! But excited to continue to support…

Proud to have participated in this study presented at #ASCO24 This is clinical research originating in the community setting helping patients with symptoms ,ePRO Trying to reduce admission to hospital Improve patients QoL Happy to say these programs work well

blog更新 - 观点：肝癌双免疫治疗（O+Y 或 STRIDE 方案）该如何用？ whyes.org/2024/viewpoint… 目前，临床上晚期肝癌患者的首选治疗是靶向联合免疫治疗（TKI 或贝伐珠单抗联合 PD-1/PD-L1 抗体），那双免疫治疗到来之后，晚期肝癌的治疗格局会发生变化吗？ #ASCO24

Reflection #4 #ASCO24: Bottom line - Early integration of palliative care improves QOL AND SURVIVAL! IMO this study is one of the most important studies ever! Dr. Joseph Greer & Dr. Jennifer Temel shared data from this simple but very meaningful study showing that #telehealth…

Benefit with adjuvant ribociclib in NATALEE was observed irrespective of menopausal status and age. QoL similar score the two arms. #ASCO24

#asco24 had a beautiful talk worth watching online if you missed by @abe_verghese whose books I just devour. Monday evening treat to engage in a more intimate venue and to fan girl a bit! Covenant of Water on your summer reading list won’t disappoint!

学会・学術集会に関する投稿で使われるハッシュタグ。これまでJSMOでは西暦4桁のタグが使われてきましたが、海外学会では #ASCO24 #ESMO23 など西暦2桁が一般的。JSMOも国際的な流れに合わせ、今年から #JSMO25 を公式ハッシュタグとして採用しました。 投稿の際は #JSMO25 をお使いください！

Best of #ASCO24 GCC tour Dubai🇦🇪 Abu Dhabi 🇦🇪 Jeddah 🇸🇦 Riyadh 🇸🇦 Muscat 🇴🇲 Doha 🇶🇦 Bahrain 🇧🇭 Kuwait 🇰🇼 6 countries in 5 intensive days, full of scientific exchange, brainstorming and networking. Impressed by infrastructure, facilities and the huge potential of the GCC region…

A great time discussing #ASCO24 Lung Cancer highlights with my international colleagues @Alfdoc2 @DrJNaidoo. LAURA, CROWN, ADRIATIC, CM816, 77T, AEGEAN and ADC updates!